Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Heskamp, Sandra ^a   Boerman, Otto C ^a   Molkenboer Kuenen, Janneke D M ^a   Wauters, Carla A ^b   Strobbe, Luc J A ^b   Mandigers, Caroline M P W ^b   Bult, Peter ^a   Oyen, Wim J G ^a   Van Der Graaf, Winette T A ^a   Van Laarhoven, Hanneke W M ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; LETROZOLE; METHOTREXATE; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SURVIVAL TIME; TREATMENT OUTCOME; AGED; BREAST NEOPLASMS; FOLLOW UP; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; UPREGULATION;

AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, IGF TYPE 1; UP-REGULATION;

EID: 84923179925     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117745     Document Type: Article

References (38)

1. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, et al. (1999) Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59: 3915-3918. PMID: 10463582
2. Hartog H, Wesseling J, Boezen HM, van der Graaf WT (2007) The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 43: 1895-1904. PMID: 17624760
3. Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28: 20-47. PMID: 16931767
4. Foekens JA, Portengen H, Janssen M, Klijn JG (1989) Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer 63: 2139-2147. PMID: 2541884
5. Peyrat JP, Bonneterre J, Beuscart R, Djiane J, Demaille A (1988) Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res 48: 6429-6433. PMID: 2972358
6. Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, et al. (2012) Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 132: 131-142. doi: 10.1007/s10549-011-1529-8 PMID: 21574055
7. Hartog H, Horlings HM, van der Vegt B, Kreike B, Ajouaou A, et al. (2011) Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res Treat 129: 725-736. doi: 10.1007/s10549-010-1256-6 PMID: 21107683
8. Railo MJ, von SK, Pekonen F (1994) The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 30A: 307-311. PMID: 8204350
9. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, et al. (1993) Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53: 3736-3740. PMID: 8339284
10. Fagan DH, Uselman RR, Sachdev D, Yee D (2012) Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res 72: 3372-3380. doi: 10.1158/0008-5472.CAN-12-0684 PMID: 22573715
11. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, et al. (1999) Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. MolEndocrinol 13: 787-796. PMID: 10319328
12. Heskamp S, Boerman OC, Molkenboer-Kuenen JD, Koornstra RH, Linn SC, et al. (2014) Dynamics of IGF-1R expression during endocrine breast cancer treatment. Mol Imaging Biol 16: 529-537. doi: 10.1007/s11307-014-0723-6 PMID: 24532107
13. Stewart AJ, Johnson MD, May FE, Westley BR (1990) Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265: 21172-21178. PMID: 2174437
14. Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, et al. (2011) Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer 18: 565-577. doi: 10.1530/ERC-10-0046 PMID: 21734071
15. Dunn SE, Hardman RA, Kari FW, Barrett JC (1997) Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 57: 2687-2693. PMID: 9205078
16. Eckstein N, Servan K, Hildebrandt B, Politz A, von JG, et al. (2009) Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 69: 2996-3003. doi: 10.1158/0008-5472.CAN-08-3153 PMID: 19318572
17. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, et al. (2009) Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69: 1951-1957. doi: 10.1158/0008-5472.CAN-08-2023 PMID: 19244128
18. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/ human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65: 11118-11128. PMID: 16322262
19. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, et al. (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13: 1198-1207. PMID: 17317830
20. Gallardo A, Lerma E, Escuin D, Tibau A, Munoz J, et al. (2012) Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106: 1367-1373. doi: 10.1038/bjc.2012.85 PMID: 22454081
21. Fu P, Ibusuki M, Yamamoto Y, Hayashi M, Murakami K, et al. (2011) Insulin-like growth factor-1 receptor gene expression is associated with survival in breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression. Breast Cancer Res Treat 130: 307-317. doi: 10.1007/s10549-011-1605-0 PMID: 21748295
22. Kim JH, Cho YH, Park YL, Sohn JH, Kim HS (2010) Prognostic significance of insulin growth factor-I receptor and insulin growth factor binding protein-3 expression in primary breast cancer. Oncol Rep 23: 989-995. PMID: 20204283
23. Gooch JL, Van Den Berg CL, Yee D (1999) Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56: 1-10. PMID: 10517338
24. Guo YS, Jin GF, Houston CW, Thompson JC, Townsend CM Jr (1998) Insulin-like growth factor-I promotes multidrug resistance in MCLM colon cancer cells. J Cell Physiol 175: 141-148. PMID: 9525472
25. Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, et al. (2012) Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 30: 256-262. doi: 10.1200/JCO.2011.37.4355 PMID: 22184397
26. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, et al. (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 11: 129-135. doi: 10.1016/S1470-2045(09)70354-7 PMID: 20036194
27. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, et al. (2011) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 29: 4541-4547. doi: 10.1200/JCO.2010.34.0000 PMID: 22025149
28. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, et al. (2009) Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27: 5800-5807. doi: 10.1200/JCO.2009.23.6745 PMID: 19786654
29. Kaufman PA, Ferrero JM, Bourgeois H, Kennecke H, De Boer R, et al. (2010) Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC) Cancer Res 70: S1-4.
30. Ramalingam SS, Spigel DR, Chen D, Steins MB, Engelman JA, et al. (2011) Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 29: 4574-4580. doi: 10.1200/JCO.2011.36.6799 PMID: 22025157
31. Watkins DJ, Tabernero J, Schmoll H, Trarbach T, Ramos FJ, et al. (2011) A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) KRAS status. J Clin Oncol 29: suppl; abstr 3501.
32. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, et al. (2008) Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 68: 8039-8048. doi: 10.1158/0008-5472.CAN-08-1712 PMID: 18829562
33. Zha J, O'Brien C, Savage H, Huw LY, Zhong F, et al. (2009) Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 8: 2110-2121. doi: 10.1158/1535-7163.MCT-09-0381 PMID: 19671761
34. Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, et al. (2012) Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer 48: 3027-3035. doi: 10.1016/j.ejca.2012.05.009 PMID: 22682017
35. Arnedos M, Nerurkar A, Osin P, A'Hern R, Smith IE, et al. (2009) Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 20: 1948-1952. doi: 10.1093/annonc/mdp234 PMID: 19570962
36. Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, et al. (2010) Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 12: R76. doi: 10.1186/bcr2719 PMID: 20920193
37. Tong LC, Nelson N, Tsourigiannis J, Mulligan AM (2011) The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study. Am J Surg Pathol 35: 545-552. doi: 10.1097/PAS.0b013e31820e6237 PMID: 21358301
38. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287-5312. PMID: 17954709